Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lifelong phylogenetic reconstruction of immune-mediated clonal trajectories in paroxysmal nocturnal hemoglobinuria.

Leukemia·2026
Same author

Chromatin landscape and epigenetic heterogeneity of acute myeloid leukaemia.

Nature·2026
Same author

Helical quaternary amine polypeptide programs membrane stress to drive immunogenic cell death and cytosolic gene delivery for cancer immunotherapy.

Biomaterials·2026
Same author

Explaining hidden mechanisms: a generative model for causal graphs with nonlinear latent factors.

Frontiers in artificial intelligence·2026
Same author

MetaCCI: meta cell-cell interaction inference and its application to CCIs characteristics of MDS.

Bioinformatics (Oxford, England)·2026
Same author

Statistical Inference of Phenotype-Specific Molecular Mechanisms from Cell Line-Specific Gene Regulatory Networks with Application to Quizartinib Sensitivity.

International journal of molecular sciences·2026

Related Experiment Video

Updated: Jun 14, 2026

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

13.7K

Differential Gene Regulatory Network Analysis between Azacitidine-Sensitive and -Resistant Cell Lines.

Heewon Park1, Satoru Miyano2,3

  • 1School of Mathematics, Statistics and Data Science, Sungshin Women's University, Seoul 02844, Republic of Korea.

International Journal of Molecular Sciences
|March 28, 2024
PubMed
Summary

Researchers identified key gene networks driving resistance to azacitidine chemotherapy in acute myeloid leukemia (AML) cells. Targeting metallothionein genes and cellular response pathways may overcome this drug resistance in AML patients.

Keywords:
acute myeloid leukemiaanti-cancer drug resistancemetallothionein gene familymolecular interplay

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.2K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.2K

Related Experiment Videos

Last Updated: Jun 14, 2026

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

13.7K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.2K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.2K

Area of Science:

  • Computational biology
  • Genomics
  • Cancer research

Background:

  • Azacitidine is a DNA methylation inhibitor used to treat acute myeloid leukemia (AML).
  • Drug resistance significantly challenges the effectiveness of azacitidine chemotherapy.
  • Understanding resistance mechanisms is crucial for improving AML treatment outcomes.

Purpose of the Study:

  • To identify molecular mechanisms underlying acquired azacitidine resistance in cancer cell lines.
  • To develop a computational strategy for analyzing cell line-specific gene networks.
  • To pinpoint differentially regulated gene networks between drug-sensitive and -resistant cells.

Main Methods:

  • Developed a computational strategy extending the DiffCoEx method for cell line-specific gene network analysis.
  • Applied the method to identify gene networks associated with azacitidine sensitivity.
  • Analyzed gene expression data to find differentially regulated networks between sensitive and resistant cell lines.

Main Results:

  • Identified a specific differentially regulated gene network in azacitidine-resistant cell lines.
  • Key genes in this network include the metallothionein gene family, C19orf33, ELF3, GRB7, IL18, NRN1, and RBM47.
  • Enriched pathways related to cellular response to metal ions (zinc, copper, cadmium) were identified.

Conclusions:

  • The metallothionein gene family and metal ion response pathways are implicated in azacitidine resistance in AML.
  • Targeting these identified genes and pathways may offer strategies to overcome azacitidine resistance.
  • The computational approach can aid precision medicine by uncovering patient-specific molecular insights for complex diseases.